Binge Eating Medication Trial, Led by The Research Institute at Lindner Center of HOPE, Shows Promising Results according to MedPage Today

Mason, OH – This May Medpage Today reported, lisdexamfetamine dimesylate (Vyvanse), a stimulant drug used to treat ADHD is showing promise for Binge Eating treatment. The article stated that Vyvanse nearly abolished eating binges in adult patients who had experienced such episodes four times a week.

Dr. Susan McElroy, Lindner Center of HOPE’s Chief Research Officer and lead investigator for the randomized, placebo-controlled trial. Dr. McElroy said that 11 weeks of treatment with the drug cut the mean rate of days with binge eating to as little as 0.1 a week. Patients assigned to placebo in the 270-patient trial had a mean bingeing rate of 1.1 days/week at the end of treatment, Dr. McElroy reported at the American Psychiatric Association’s (APA) annual meeting.

To read the article, visit http://www.medpagetoday.com/MeetingCoverage/APA/39248

Lindner Center of HOPE provides excellent, patient-centered, scientifically-advanced care for individuals suffering with mental illness. A state-of-the-science, mental health center and charter member of the National Network of Depression Centers, the Center provides psychiatric hospitalization and partial hospitalization for individuals age 12-years-old and older, outpatient services for all ages, diagnostic and short-term residential services for adults, intensive outpatient program for substance abuse and co-occurring disorders for adults and research. The Center is enhanced by its partnership with UC Health as its clinicians are ranked among the best providers locally, nationally and internationally. Together Lindner Center of HOPE and UC Health offer a true system of mental health care in the Greater Cincinnati area and across the country. The Center is also affiliated with the University of Cincinnati (UC) College of Medicine.

This entry was posted in General Announcements, Lindner Center of HOPE News, News, Research. Bookmark the permalink.